Evidence map›Paper›PMID 36589726›Full record

ReviewLiver cancer2022

Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).

Yu Yang, Juxian Sun, Mengchao Wu, Wan Yee Lau, Shusen Zheng, Xue-Hao Wang, Xiaoping Chen, Jia Fan, Jiahong Dong, Jianqiang Cai and 47 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Liver cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

57 authors at 20 institutions in 2 countries.

Yu YangDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Juxian SunDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Mengchao WuDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Wan Yee LauDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Shusen ZhengDepartment of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Hangzhou, China.
Xue-Hao WangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiaoping ChenHepatic Surgery Center, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Jia FanDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai, China.
Jiahong DongDepartment of Hepatobiliary and Pancreas Surgery, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China.
Jianqiang CaiDepartment of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Minshan ChenDepartment of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yongjun ChenDepartment of Hepatobiliary Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhangjun ChengDepartment of Hepatobiliary Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Chaoliu DaiDepartment of Hepatobiliary and Spleenary Surgery, The Affiliated Shengjing Hospital, China Medical University, Shenyang, China.
Jianzhen ShanDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Cheng-You DuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chihua FangDepartment of Hepatobiliary Surgery, Zhujiang Hospital, First Military Medical University, Guangzhou, China.
Heping HuDepartment of Gastroenterology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Zhili JiDepartment of General Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Weidong JiaDepartment of General Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Gong LiDepartment of Radiation Oncology, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China.
Jing LiDepartment of Hepatobiliary Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Jiangtao LiDepartment of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Chang LiuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Fubao LiuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yong MaDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Yilei MaoDepartment of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing, China.
Zuoxing NiuDepartment of Gastroenterology, Shandong Cancer Hospital, Jinan, China.
Jie ShenDepartment of Medical Oncology, Cancer Center, Nanjing Drum Tower Hospital, Medical College of Nanjing University, Nanjing, China.
Jie ShiDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Xuetao ShiDepartment of Hepatobiliary Surgery, Shandong Cancer Hospital, Jinan, China.
Wenjie SongDepartment of Hepatobiliary Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.
Hui-Chuan SunDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai, China.
Guang TanDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Ran TaoDepartment of Hepatobiliary Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China.
Xiaohu WangDepartment of Radiation Oncology, Gansu Cancer Hospital, Lanzhou, China.
Tianfu WenDepartment of Liver Surgery, Center of Liver Transplantation, West China Hospital, Sichuan University, Chengdu, China.
Liqun WuDivision of Hepatobiliary Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Jinglin XiaLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Bang-De XiangDepartment of Hepatobiliary Surgery, Cancer Hospital Affiliated to Guangxi Medical University, Nanning, China.
Maolin YanDepartment of Hepatobiliary and Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, China.
Mingang YingDepartment of Abdominal Surgery, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital, Fuzhou, China.
Ling ZhangDepartment of Hepatobiliary Surgery, Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Xuewen ZhangDepartment of Hepatobiliary and Pancreas Surgery, The Second Hospital of Jilin University, Changchun, China.
Zhao Chong ZengDepartment of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yubao ZhangDepartment of Hepatobiliary Surgery, Cancer Hospital Affiliated to Harbin Medical University, Harbin, China.
Zhiwei ZhangDepartment of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jie ZhouDepartment of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Cuncai ZhouDepartment of Hepatobiliary Surgery, Jiangxi Provincial Cancer Hospital, Jiangxi, China.
Jun ZhouDepartment of Medical Oncology, Beijing Cancer Hospital, Beijing, China.
Ledu ZhouDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, China.
Xinmin ZhouDepartment of Gastroenterology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Ji ZhuDepartment of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China.
Zhenyu ZhuDepartment of Hepatobiliary Surgery, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Qi ZhangDepartment of Hepatobiliary Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Qiu LiDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Shuqun ChengDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Second Military Medical University · CNFudan University · CNSichuan University · CNSun Yat-sen University · CNArmy Medical University · CNBeijing Tsinghua Chang Gung Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNHarbin Medical University · CNJiangsu Province Hospital · CNPeking University · CNShandong Tumor Hospital · CNTongji Hospital · CNXijing Hospital · CNAnhui Medical University · CNCancer Hospital of Chinese Academy of Medical Sciences · CNCapital Medical University · CNCentral South University · CNChina Medical University · CNChinese PLA General Hospital · CNChinese University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are first diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment. Summary: In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular-targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the "Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021)" based on current clinical studies and clinical medication experience for reference in China. Key Messages: The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients, and potential population for immunotherapy.

Indexed as

ConsensusHepatocellular carcinomaImmune checkpoint inhibitors

Identifiers

PMID36589726
PMCPMC9801175
OpenAlexW4286009076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.